Same huge potential..... and should be valued at a percentage of...

Same huge potential..... and should be valued at a percentage of that (like most other biotechs).

Best of Breed Product. 8M tests in the US per year... 750K in UK, maybe 4M in Europe... plus asia, india etc etc...

Worldwide could easily be 20M tests per year, at $75 a test.... big big market... ($1.5B per annum).

Even if they get 10% of the market (which would be unrealistically low for a best in breed product), that is $150M a year..... P.E. of 10 (again low), future market cap $1.5B.

Current cap around $20M. Can you see the upside?

As usual, this is very early days, but not as early as some other bios. Like ADO, product is hitting the market, and the company has been ignored by the market. That is now changing.

PRR for example has a market cap of $100M.... one could easily argue that HTX should be at the very least the same sort of market cap.